secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-047099
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo posts Q3 net income $10.7M; FDA clears Accelerated Approval path for Fabry gene therapy ST-920
--------------------------------------------------------------------------------

- Net income $10.7M ($0.04 diluted EPS) vs net loss $104.2M ($0.59 loss) in Q3 2023.
- Revenue $49.4M (up from $9.4M), driven by $49.2M from Genentech collaboration.
- FDA agrees Phase 1/2 STAAR data can support Accelerated Approval for ST-920 in Fabry disease; BLA submission expected H2 2025.
- Received $50M from Genentech upfront/milestones; eligible for up to $1.9B in additional milestones plus tiered royalties.
- Cash $39.2M; expects to fund operations into Q1 2025 including $10M milestone from Genentech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/0001628280-24-047099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828024047099/sgmo-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-047099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer